Efficacy of metronidazole and miconazole vaginal co-formulation for bacterial vaginosis and vulvovaginal candidiasis

Recurrent vulvovaginal infections being an epidemiological and clinical issue also have social and psychological implications. As a result, the development of the effective diagnostic strategies and therapeutic approaches to female genital infections is important. This paper reviews the most common vulvovaginal infections, i.e., bacterial vaginosis and vulvovaginal candidiasis. Topical metronidazole and miconazole vaginal dosage forms prescribed for these relevant obstetrical gynecological disorders are highlighted. Although numerous domestic and foreign publications on the clinical efficacy of this combination are available, dose reductions and the minimum therapeutically effective doses for bacterial vaginosis, vulvovaginal candidiasis, and mixed vaginitis are still challenging entities. The data on the efficacy of a novel dosage form, Gynocaps® vaginal capsules, containing low doses of miconazole (100 mg) and metronidazole (100 mg) are addressed. The treatment has resulted in microbiological cleaning, the normalization of vaginal WBC count, and the improvement of vaginal florocenosis. In addition, easy-to-use vaginal capsules ensure treatment adherence.KEYWORDS: bacterial vaginosis, vulvovaginal candidiasis, metronidazole, miconazole nitrate, vaginal capsules.FOR CITATION: Markova E.A. Efficacy of metronidazole and miconazole vaginal co-formulation for bacterial vaginosis and vulvovaginal candidiasis. Russian Journal of Woman and Child Health. 2020;3(3):205–210. DOI: 10.32364/2618-8430-2020-3-3-205-210.